Comparative Evaluation of Vitamin C and Injectable-platelet Rich Fibrin in the Management of Thin Gingival Phenotype

• Status: Not yet recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

• The goal is to compare between the effect of vitamin C and Injectable-platelet rich fibrin in the management of thin gingival phenotype.

• The main question: ln patients with thin phenotype, will injecting Vitamin C with micro needles increase the gingival thickness compared to injecting injectable-platelet rich fibrin with micro needles?

• After enrolment, periodontal examination and measurement of periodontal probing depth (PD), patients with a high periodontal probe visibility in the anterior teeth will be identified. These patients will undergo gingival thickness (GT) measurement using trans gingival probing technique in the anterior teeth, and those with a measured GT of ≤ 1.5mm will be diagnosed with thin phenotype.

• Keratinized tissue width will be measured.

• Micro needle the gingival mucosa by using derma pen device which will be used in intermittent motion on the sextant gingival area for 30-40 seconds/tooth. When bleeding pinpoints observed on all areas of attached gingiva.

• Intervention group: Vitamin C injection will be injected with microneedle at two points for each site in the attached gingiva of right or left (split mouth) at 3 mm apical to the free gingival margin in the facial side of the tooth until the blanching of the gingiva will be seen and apical to the mucogingival junction.

• Control group:

1.Preparation and administration of injectable platelets rich fibrin (i-PRF). I-PRF will be injected on the site with thin gingival phenotype on the other side of the jaw in the same patient (split mouth technique) with micro needling same way as vitamin C group.

3.Vitamin C and I-PRF will again be injected at the same site after 1 week and after 2 weeks from the baseline final injection which will be given.

Outcomes: The results for the mean gingival thickness (GT), keratinized tissue width (kTW), pocket depth (PD), and gingival index (GI) at baseline, 1 month, 3 months and after 6 months

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Ascorbic Acid

Criteria

Inclusion Criteria:

Systemically healthy individuals of age ≥ 18 to 40 years with absence of active periodontal disease.

• Having thin gingival phenotype <1.5mm.

• No systemic disease according to Modified Cornell Medical Index health questionnaire.

• Non-smoker.

• Full mouth plaque index (PI) and full-mouth bleeding on probing (BOP) score of ≤ 15%.

• No malocclusion, crowding, fillings, missing or supernumerary mandibular anterior teeth.

• No blood-borne conditions.

Exclusion Criteria:

• Active orthodontic treatment.

• Previous periodontal surgery.

• Systemic disease.

• Use of blood thinners.

• Use of any drugs that might lead to gingival enlargement.

• Mucogingival stress, bruxism.

• Pregnancy or lactation.